About MiMedx Group (MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: MDXG
- CUSIP: N/A
- Previous Close: $9.10
- 50 Day Moving Average: $8.38
- 200 Day Moving Average: $8.68
- 52-Week Range: $6.64 - $10.02
- Trailing P/E Ratio: 82.73
- Foreward P/E Ratio: 25.28
- P/E Growth: 1.92
- Market Cap: $964.91M
- Outstanding Shares: 106,034,000
- Beta: 0.97
- Net Margins: 8.75%
- Return on Equity: 18.18%
- Return on Assets: 12.64%
- Current Ratio: 2.56%
- Quick Ratio: 2.12%
Companies Related to MiMedx Group:
Earnings History for MiMedx Group (NASDAQ:MDXG)Earnings History by Quarter for MiMedx Group (NASDAQ:MDXG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/24/2017|| || || || || || || || |
|2/23/2017||Q416||$0.08||$0.05||$71.13 million||$69.90 million||View||Listen|
|10/27/2016||Q316||$0.06||$0.06||$63.18 million||$64.40 million||View||Listen|
|7/26/2016||Q216||$0.07||$0.05||$56.49 million||$57.00 million||View||Listen|
|4/26/2016||Q116||$0.05||$0.04||$54.05 million||$53.40 million||View||Listen|
|2/23/2016||Q415||$0.06||$0.12||$51.84 million||$51.80 million||View||Listen|
|10/29/2015||Q315||$0.06||$0.06||$48.61 million||$49.00 million||View||Listen|
|7/30/2015||Q215||$0.04||$0.05||$45.03 million||$45.68 million||View||Listen|
|2/26/2015||Q414||$0.03||$0.03||$38.15 million||$39.60 million||View||Listen|
|10/30/2014||Q314||$0.02||$0.03||$33.50 million||$33.50 million||View||Listen|
|4/25/2014||Q114||($0.02)||($0.01)||$19.09 million||$19.60 million||View||Listen|
|2/26/2014||Q4||($0.01)||($0.04)||$18.31 million||$18.00 million||View||Listen|
|7/31/2013||Q2 2013||($0.01)||($0.01)||$12.94 million||$13.52 million||View||Listen|
|5/1/2013||Q1 2013||($0.02)||($0.02)||$11.34 million||$11.56 million||View||Listen|
Earnings Estimates for MiMedx Group (NASDAQ:MDXG)
Current Year EPS Consensus Estimate: $0.30 EPS
Next Year EPS Consensus Estimate: $0.36 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for MiMedx Group (NASDAQ:MDXG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MiMedx Group (NASDAQ:MDXG)
Insider Ownership Percentage: 12.30%Insider Trades by Quarter for MiMedx Group (NASDAQ:MDXG)
Institutional Ownership Percentage: 50.47%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/6/2016||William Charles Taylor||Insider||Sell||20,400||$7.55||$154,020.00|| |
|8/1/2016||William Charles Taylor||Insider||Sell||29,112||$7.55||$219,795.60|| |
|6/16/2016||William Charles Taylor||COO||Sell||24,333||$7.52||$182,984.16|| |
|5/20/2016||Parker H Petit||CEO||Buy||20,000||$6.99||$139,800.00|| |
|5/17/2016||Parker H Petit||CEO||Buy||30,000||$6.82||$204,600.00|| |
|5/13/2016||Parker H Petit||CEO||Buy||40,000||$6.75||$270,000.00|| |
|5/12/2016||Parker H Petit||CEO||Buy||50,000||$6.74||$337,000.00|| |
|11/13/2015||Charles Robert Evans||Director||Buy||10,000||$7.84||$78,400.00|| |
|11/10/2015||Parker H Petit||CEO||Buy||131,925||$7.58||$999,991.50|| |
|10/30/2015||Alexandra O. Haden||General Counsel||Buy||4,150||$7.92||$32,868.00|| |
|5/28/2015||Larry W Papasan||Director||Sell||5,958||$10.09||$60,116.22|| |
|5/18/2015||William Charles Taylor||COO||Sell||150,000||$10.01||$1,501,500.00|| |
|10/31/2014||William Charles Taylor||COO||Sell||150,000||$10.01||$1,501,500.00|| |
|7/1/2014||William Charles Taylor||COO||Sell||150,000||$7.50||$1,125,000.00|| |
|1/17/2014||Parker Petit||CEO||Sell||150,000||$8.28||$1,242,000.00|| |
|8/28/2013||William Charles Taylor||COO||Sell||9,800||$6.15||$60,270.00|| |
|8/7/2013||William Charles Taylor||COO||Sell||183,765||$6.21||$1,141,180.65|| |
|5/16/2013||Steve Gorlin||Director||Sell||30,000||$6.46||$193,800.00|| |
Headline Trends for MiMedx Group (NASDAQ:MDXG)
Latest Headlines for MiMedx Group (NASDAQ:MDXG)
|MiMedx To Present At The 16th Annual Needham Healthcare Conference|
finance.yahoo.com - March 24 at 6:30 PM
|MiMedx Group Inc (MDXG) Rating Increased to B at TheStreet|
www.americanbankingnews.com - March 22 at 8:13 AM
|MIMEDX GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - March 20 at 4:42 PM
|MiMedx Group Inc (MDXG) Upgraded to B by TheStreet|
www.americanbankingnews.com - March 19 at 9:13 PM
|MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors|
finance.yahoo.com - March 19 at 5:44 PM
|MIMEDX GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obl|
biz.yahoo.com - March 13 at 6:11 PM
|MiMedx Group, Inc. Shareholder Call scheduled for 10:30 am ET today|
biz.yahoo.com - March 9 at 6:17 PM
|MiMedx To Present At Canaccord's 12th Annual Musculoskeletal Conference|
us.rd.yahoo.com - March 8 at 7:13 PM
|Coverage initiated on MiMedx Group by Piper Jaffray|
finance.yahoo.com - March 3 at 6:30 PM
|MiMedx to Host Shareholder call on March 9, 2017 to present various strategic and tactical initiatives to shareholders|
finance.yahoo.com - March 2 at 9:39 AM
|MiMedx Audit Committee Announces Completion Of Its Investigation|
us.rd.yahoo.com - March 1 at 11:33 PM
|MIMEDX GROUP, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 1 at 6:32 PM
|MIMEDX GROUP, INC. Financials|
finance.yahoo.com - February 28 at 6:36 PM
|Edited Transcript of MDXG earnings conference call or presentation 23-Feb-17 3:30pm GMT|
finance.yahoo.com - February 24 at 7:44 PM
|Noteworthy Thursday Option Activity: SPLK, MDXG, ZBRA|
www.nasdaq.com - February 23 at 6:31 PM
|MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi|
biz.yahoo.com - February 23 at 6:31 PM
|Q4 2016 MiMedx Group Inc Earnings Release - Before Market Open|
biz.yahoo.com - February 23 at 7:47 AM
|MiMedx Announces 2016 Record Results|
finance.yahoo.com - February 23 at 7:47 AM
|First Week of April 21st Options Trading For MiMedx Group - TheStreet.com|
www.thestreet.com - February 22 at 11:44 PM
|MiMedx Announces Release Date for 2016 Full Year Results|
finance.yahoo.com - February 16 at 6:04 PM
|Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery|
finance.yahoo.com - February 7 at 7:47 PM
|MiMedx Group (MDXG) Raise Buyback Plan by $10M - StreetInsider.com|
www.streetinsider.com - February 6 at 6:34 PM
|MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program|
us.rd.yahoo.com - February 6 at 9:58 AM
|MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year|
us.rd.yahoo.com - February 3 at 7:12 PM
|1:24 pm MiMedx Group comments on the FDA's recently published 2017 calendar year guidance agenda|
us.rd.yahoo.com - February 3 at 7:12 PM
|Atlanta biomedical company MiMedx claims 'outlandish scheme' by employees|
www.bizjournals.com - February 2 at 7:19 PM
|MiMedx Group (MDXG) Says Study Confirms dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction - StreetInsider.com|
www.streetinsider.com - January 26 at 9:21 PM
|Scientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction|
finance.yahoo.com - January 24 at 7:14 PM
|2:10 pm MiMedx Group announces the latest peer-reviewed scientific study of the MiMedx dehydrated human amnion/chorion membrane allografts has been electronically published in the Journal of Cardiology & Cardiovascular Therapy|
finance.yahoo.com - January 24 at 7:14 PM
|Falling Earnings Estimates Signal Weakness Ahead for MiMedx Group (MDXG) - Yahoo Finance|
finance.yahoo.com - January 21 at 5:16 AM
Frequently Asked Questions for MiMedx Group (NASDAQ:MDXG)
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How were MiMedx Group's earnings last quarter?
MiMedx Group Inc (NASDAQ:MDXG) announced its quarterly earnings results on Thursday, February, 23rd. The company reported $0.05 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.03. The business had revenue of $69.90 million for the quarter, compared to analyst estimates of $71.13 million. MiMedx Group had a return on equity of 18.18% and a net margin of 8.75%. The company's revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 EPS.
When will MiMedx Group make its next earnings announcement?
MiMedx Group is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.
What guidance has MiMedx Group issued on next quarter's earnings?
MiMedx Group issued an update on its FY17 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of $0.31-0.33 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.32. The company issued revenue guidance of $302-307 million, compared to the consensus revenue estimate of $304.61 million.
Where is MiMedx Group's stock going? Where will MiMedx Group's stock price be in 2017?
6 brokerages have issued 1-year price objectives for MiMedx Group's stock. Their forecasts range from $9.00 to $12.00. On average, they expect MiMedx Group's stock price to reach $11.00 in the next twelve months.
What are analysts saying about MiMedx Group stock?
Here are some recent quotes from research analysts about MiMedx Group stock:
- 1. Needham & Company LLC analysts commented, "MDXG’s 4Q16 revenue was below its 1/9/17 preannouncement (due to increased sales returns and allowances reserves as it transitions from using AvKare) while its adjusted EBITDA beat consensus and adjusted EPS missed consensus. Management reiterated its 2017 guidance. Receivables were 86 days at the end of 4Q16, which is down from 89 days at the end of 3Q16; MDXG continues to add staff to improve collections. While MDXG’s revenue growth reached 35% in 4Q16 and 1Q17 revenue guidance implies 30-36% growth, guidance implies only 23-25% for the full year which strikes us as conservative. With the potential for meaningful upside to consensus and shares at a steep discount to peers (2017E EV/sales of 2.7x vs. small/ mid-cap growth peers at 4.7x), we reiterate our Strong Buy rating." (2/23/2017)
- 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (2/21/2017)
Are investors shorting MiMedx Group?
MiMedx Group saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 26,505,439 shares, an increase of 2.0% from the February 28th total of 25,993,978 shares. Based on an average daily volume of 952,930 shares, the days-to-cover ratio is presently 27.8 days. Approximately 26.7% of the shares of the stock are short sold.
Who owns MiMedx Group stock?
MiMedx Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock, Inc (10.40%), State Street Corp (2.88%), Senzar Asset Management LLC (1.18%), Disciplined Growth Investors Inc. MN (0.69%), Russell Investments Group Ltd. (0.59%) and Guggenheim Capital LLC (0.36%). Company insiders that own MiMedx Group stock include Alexandra O Haden, Charles Robert Evans, Larry W Papasan, Parker H Petit and William Charles Taylor.
Who sold MiMedx Group stock? Who is selling MiMedx Group stock?
MiMedx Group's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, GSA Capital Partners LLP, Metropolitan Life Insurance Co. NY, Raymond James Financial Services Advisors Inc. and Putnam Investments LLC.
Who bought MiMedx Group stock? Who is buying MiMedx Group stock?
MiMedx Group's stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Russell Investments Group Ltd., State Street Corp, Millrace Asset Group Inc., Guggenheim Capital LLC, Disciplined Growth Investors Inc. MN, Bayesian Capital Management LP and Cutter & CO Brokerage Inc.. Company insiders that have bought MiMedx Group stock in the last two years include Alexandra O Haden, Charles Robert Evans and Parker H Petit.
How do I buy MiMedx Group stock?
Shares of MiMedx Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of MiMedx Group stock cost?
One share of MiMedx Group stock can currently be purchased for approximately $9.10.
MiMedx Group (MDXG) Chart for Saturday, March, 25, 2017